This induces GI tract mucosal inflammation and promotes IBD pathogenesis.86,87 A second hypothesis is that IL-17 inhibition changes the colonic fungal microbiome composition via unchecked Candida albicans proliferation, which predisposes susceptible individuals to developing de novo IBD.88 This evidence concerns the gene IL17A and inflammatory bowel disease.